Breaking News, Financial News

Biogen Idec

Tysabri, Avonex revenues continue growth

Biogen Idec 2Q10

2Q Revenues: $1.2 billion (+11%)

2Q Earnings: $294 million (+103%)

YTD Revenues: $2.3 billion (+9%)

YTD Earnings: $515 million (+31%)

Comments: Avonex revenues grew 6% in 2Q10 and YTD to $628 million and $1.2 billion, respectively. Tysabri revenues were up 17% to $219 million in the quarter, and 24% to $438 million for the year. The company estimates that 52,700 patients worldwide are on commercial or clinical Tysabri. R&D expenses dropped 20% in 2Q10 to $332 million, and fell 8% to $639 million YTD.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters